Search results
Sep 28, 2022 · Selecting a proprietary name for a drug that is both attractive to the market and approved by the authorities is not easy. Counsel should be involved at an early stage to avoid potential pitfalls.
nonproprietary (ˌnɒnprəˈpraɪətərɪ) adj 1. (Pharmacology) of or denoting a drug or agent that is not manufactured under a trade name 2. not privately owned and ...
Jul 28, 2014 · For the first time, the Agency agreed to a process and timelines for notifying applicants of the tentative acceptance or nonacceptance of a proposed proprietary name. These proprietary name review performance goals and timelines are separate from the timelines for approval of underlying new drug applications and biologics license applications.
Apr 5, 2011 · Procedure for USAN Name Selection. The process of assigning a United States Adopted Name (USAN), referred to as a "negotiation," begins when a pharmaceutical firm or its representative files an application to name the substance . It ends with the statement of adoption a document that formally assigns a USAN to a specific substance.
1 INTRODUCTION. This review evaluates the proposed proprietary name, Ayvakit, from a safety and misbranding perspective. The sources and methods used to evaluate the proposed proprietary name are outlined in the reference section and Appendix A respectively. Blueprint did not submit an external name study for this proposed proprietary name.
Jun 7, 2023 · Proprietary and non-proprietary name If a drug does not have a proprietary name, the established name of the drug should be included in the proprietary name field Dosage form and route of ...
Mar 21, 2021 · For example, in the US, the non-proprietary name is appended with a unique, randomly generated, four-letter sequence, but in the EU, all products (innovator and biosimilar[s]) with the same active ingredient share the same non-proprietary name (i.e., no four-letter suffix) . To improve traceability in the EU, the brand name is used ...